法国蒙彼利埃18-25岁女性HPV感染与血清学状态:接种与未接种比较
该研究在法国蒙彼利埃纳入150名18至25岁女性,在入组时及一个月后采集宫颈拭子、血样并收集问卷,分析HPV感染与抗体状态。结果显示接种状态对HPV感染有最强保护效应, alphapapillomavirus检测的比值比为0.45(95%CI:0.22-0.58),且接种女性中HPV51显著低 representation。年龄、性伴侣数、体质指数和避孕状态也影响HPV检测与共感染。
要点
- 接种状态对HPV感染保护效应最强,OR=0.45(95%CI:0.22-0.58)。
- HPV51在接种女性中显著低representation,提示交叉保护可能。
- 年龄、性伴侣数、BMI和避孕状态与HPV检测及共感染相关。
核心结论
- 接种状态是HPV感染的最强保护因素,OR=0.45(95%CI:0.22-0.58)。
- 接种状态对型特异性IgG血清学状态有主要解释作用。
- HPV51在接种女性中显著低representation,提示疫苗交叉保护效应值得进一步研究。
研究设计与样本
- 在法国蒙彼利埃纳入150名18至25岁女性,接种状态在队列中均衡。
- 入组时及一个月后采集宫颈拭子、血样和问卷(人口学与行为变量)。
主要发现
- 总体最常检出的基因型为致癌非疫苗型HPV51、HPV66、HPV53和HPV52。
- 接种状态对alphapapillomavirus检测的OR=0.45(95%CI:0.22-0.58)。
- 年龄、性伴侣数、体质指数和避孕状态对HPV检测及共感染有显著影响。
- 型特异性IgG血清学状态 largely由接种状态解释,IgM血清阳性 best由入组时HPV检测解释。
- 接种对基因型患病率有强显著效应,接种女性中HPV51显著低representation。
临床怎么用
- 在低接种率国家,理解生殖道HPV感染仍是重要公共卫生问题。
- 接种状态与HPV感染及血清学状态密切相关,支持接种在年轻女性中的保护作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Understanding genital infections by Human papillomaviruses (HPVs) remains a major public health issue, especially in countries where vaccine uptake is low. We investigate HPV prevalence and antibody status in 150 women (ages 18 to 25) in Montpellier, France. At inclusion and one month later, cervical swabs, blood samples and questionnaires (for demographics and behavioural variables) were collected. Oncogenic, non-vaccine genotypes HPV51, HPV66, HPV53, and HPV52 were the most frequently detected viral genotypes overall. Vaccination status, which was well-balanced in the cohort, showed the strongest (protective) effect against HPV infections, with an associated odds ratio for alphapapillomavirus detection of 0.45 (95% confidence interval: [0.22;0.58]). We also identified significant effects of age, number of partners, body mass index, and contraception status on HPV detection and on coinfections. Type-specific IgG serological status was also largely explained by the vaccination status. IgM seropositivity was best explained by HPV detection at inclusion only. Finally, we identify a strong significant effect of vaccination on genotype prevalence, with a striking under-representation of HPV51 in vaccinated women. Variations in HPV prevalence correlate with key demographic and behavioural variables. The cross-protective effect of the vaccine against HPV51 merits further investigation.
引用
- Murall CL, Reyné B, Selinger C, et al. HPV cervical infections and serological status in vaccinated and unvaccinated women. Vaccine. 2020. PMID: 33168348. doi:10.1016/j.vaccine.2020.10.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。